创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

Advanced Search
SHI Yingzi, ZHAO Yang. Advantages and Challenges of China's Enterprises Conducting Clinical Trials of Innovative Drugs in both China and US[J]. Progress in Pharmaceutical Sciences, 2019, 43(12): 900-907.
Citation: SHI Yingzi, ZHAO Yang. Advantages and Challenges of China's Enterprises Conducting Clinical Trials of Innovative Drugs in both China and US[J]. Progress in Pharmaceutical Sciences, 2019, 43(12): 900-907.
shu

Advantages and Challenges of China's Enterprises Conducting Clinical Trials of Innovative Drugs in both China and US

    Graphical Abstract
    • Abstract
  • Increasing number of domestic pharmaceutical companies choose to conduct clinical trials of innovative drugs in both China and US and seek to launch in overseas markets. As of June 2019, 85 products under investigational new drug (IND) application have been approved both in China and US. This paper analyzes the characteristics of these products as well as the advantages and challenges of China's enterprises conducting clinical trials of innovative drugs in both China and US.
    • FullText(HTML)
  • loading
    • References (9)
    • Related Articles

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return